Coronavirus antibodies may only last a MONTH: 独房s '拒絶する／低下する 意味ありげに' within just four WEEKS of hospital 発射する／解雇する, Chinese 熟考する／考慮する finds in worrying blow to hopes of Covid-19 免疫

調印するs of 免疫 消える quickly from 本気で-ill coronavirus 患者s in いっそう少なく than a month after they are 発射する／解雇するd from hospital, a 熟考する／考慮する has 設立する.

研究員s looking at antibodies ? 実体s in the 血 that develop 免疫 against the ウイルス ? have 設立する they 減少（する） off はっきりと once a 患者 as 回復するd.

The finding is worrying news for hopes that people will become 免疫の to Covid-19 after having it for the first time.?

Most people who were sent home from hospital after having the 病気 did show 調印するs of antibodies ? 示唆するing their 団体／死体s had learned to 保護する themselves from the ウイルス ? but they were not strong.

Some 81 per cent of 患者s had the antibodies, the Chinese 熟考する／考慮する 設立する, but only a 'small 部分' of them had any with the ability to neutralise ? or kill ? the ウイルス.

Whether people become 免疫の to Covid-19 after having it remains a mystery.?

There are 調印するs that the 団体／死体 learns to fend it off but also growing numbers of '信頼できる' 事例／患者s where people get reinfected.

If the 団体／死体 cannot 保持する antibodies over the long-称する，呼ぶ／期間／用語 it could mean that a ワクチン may not 申し込む／申し出 永久の 保護, as scientists and politicans around the world are hoping one will.

Scientists 監視するd 19 非，不，無-厳しい and seven 厳しい Covid-19 患者s for a month and three weeks to 決定する how their 団体／死体s produced antibodies (在庫／株 image)

Scientists at?南京 University 医療の School in 中国 監視するd 19 非，不，無-厳しい and seven 厳しく ill Covid-19 患者s for a month and three weeks to 決定する the progression of their antibody 返答.

They 設立する that the 患者s had a 変化させるing level of antibody 返答s, with only a 'small 部分' developing a potent level of neutralisation activity. The scientists did not say 正確に／まさに how many people had this.?

The 熟考する／考慮する 示すs that three to four weeks after hospital 発射する／解雇する, the neutralising activity of antibodies from 回復するd 患者s 拒絶する／低下するd 意味ありげに.

The authors wrote: 'The world is 直面するing an 前例のない challenge with communities and economies 影響する／感情d by the growing pandemic of coronavirus 病気 2019 (Covid-19)...

'The 開発 of antibody 返答 to Sars-CoV-2, the ウイルス that 原因（となる）s Covid-19, started to be 報告（する）／憶測d but remained 大部分は elusive.

'Understanding the adaptive 返答s where the 団体／死体 makes antibodies that 特に 貯蔵所d to the Sars-CoV-2 の中で Covid-19 患者s 供給するs 根底となる （警察などへの）密告，告訴（状） for developing 効果的な 治療 and 予防の ワクチン.'

Past 熟考する／考慮するs have 設立する the opposite to this one ? that antibodies can last for months after someone is sick with the 病気 ? while others have 公式文書，認めるd that people barely build up 免疫 at all.

There is also some 審議 about whether the severity of illness plays a factor.

People who get 本気で ill and hospitalised tend to have a stronger 免疫の reaction and therefore are more likely to be 保護するd in 未来.

While those who have only 穏やかな or even unnoticeable symptoms may not develop 免疫 at all.

There is no 保証（人） that people's 団体／死体s do 保護する themselves, and scientists will only be able to 確認する this with time.

Earlier this week, Health 長官 Matt Hancock said there were now '信頼できる' 報告（する）／憶測s 現れるing of people getting the illness more than once ? something that had been considered ありそうもない during the 頂点（に達する） of the 突発／発生.??

He told 議会's Health and Social Care 委員会 that the first '信頼できる' 事例／患者s of coronavirus reinfection were starting to be seen.

'We have also just started to see the first 信頼できる 事例／患者s of reinfection and, through genomic 分析, you can see it is a different 病気 to the one the person got the first time around.

'But in all the 事例／患者s that I have seen it has been an asymptomatic second 感染 that has been 選ぶd up through asymptomatic 実験（する）ing.'

Mr Hancock's latter point 示唆するs that people do not become noticeably ill the second time around and do not get symptoms.

Commenting on the 最近の 熟考する／考慮する,?Danny Altmann, professor of immunology at 皇室の College London, and British Society for Immunology 広報担当者, said: 'After the 初期の 出版（物）s about Sars-CoV-2 antibody assays and levels, important papers are starting to 現れる which look at specificity and durability of the 返答 in more 詳細（に述べる）.

'熟考する／考慮するs like this are a 決定的な part of the 'work-in-進歩' to make sen se of who has 免疫 and how long for.

'This paper makes a number of points: the gold-基準 in 査定する／（税金などを）課すing the antibody 返答 to a ウイルス is 手段ing ability to neutralise the 入ること／参加（者） of ウイルス into 独房s, although this is not one of the routinely 利用できる 実験（する）s.

'Most convalescent 患者s show this 返答, though, importantly, 20% do not. Also, this antibody level 拒絶する／低下するs in most people by the time of their follow-up 任命 a month later.

'Once again, 証拠 shows that the half-life of these antibodies in the 血 is not 特に 支えるd.

'We don't know to what extent this is bad news unless we know the extent to which the white 血 独房s that make the antibody (B 独房s) are up and ready to defend against any repeat attack.'

The 熟考する／考慮する was published in the 科学の 定期刊行物 PLOS Pathogens.?